FREE Case Review (866) 588-0600

Zinbryta Lawsuit

A global withdrawal has been issued for Zinbryta (generic: daclizumab), a multiple sclerosis (MS) treatment linked to inflammatory brain disorders (encephalitis and meningoencephalitis), liver failure, and death.
Awards & recognition

The new-generation multiple sclerosis treatment Zinbryta (generic: daclizumab) has been removed from the global market after being linked to serious side effects including inflammatory brain disorders (encephalitis and meningoencephalitis), brain inflammation, and death.

Free Confidential Lawsuit Evaluation: If you or a loved one has been injured by the side effects of Zinbryta, you should contact our law firm immediately. You may be entitled to compensation by filing a suit against the manufacturer and our lawyers can help.

What is Zinbryta?

Developed in a joint partnership between Biogen and Abbvie, Inc., Zinbryta is an injectable disease modifying drug (DMD) used to treat adult patients with relapsing forms of multiple sclerosis (MS). The medicine works by binding to immune cells (lymphocytes or white blood cells) and reducing the activity of cells involved in the immune attack that cause damage associated with multiple sclerosis.

What’s the problem?

Zinbryta was removed from the global market in March 2018 after being linked to multiple reports of severe and potentially deadly brain problems, including encephalitis and meningoencephalitis, as well as at least 3 deaths in patients in the U.S.

"Given the nature and complexity of adverse events being reported, characterizing the evolving benefit/risk profile of Zinbryta will not be possible going forward given the limited number of patients being treated," Biogen and Abbvie, Inc., said in a statement. "Therefore, Biogen and AbbVie believe it is in the best interest of patients to voluntarily withdraw worldwide marketing authorizations for Zinbryta."

The move came as the European Medicines Agency (EMA) moved to recall Zinbryta amid reports of deaths and brain inflammation.

Zinbryta Side Effects

  • Liver failure
  • Drug-induced hepatitis
  • Inflammatory encephalitis
  • Menigeoncephalitis
  • Death

These side effects have been reported to occur at any time during treatment with Zinbryta, including up to 4 months after discontinuing the drug.

Related Articles:

Can I File a Lawsuit?

Only a qualified attorney can determine whether you are eligible to file a lawsuit against the makers of Zinbryta, which is why we are currently offering free case evaluations. Simply fill out the confidential evaluation form below to contact our law firm now.

Most cases involving pharmaceuticals allege that a drug was sold with design, manufacturing, and/or marketing defects, which typically refers to a company’s failure to warn of a certain side effect. In the case of Zinbryta, our attorneys suspect that patients may be able to take legal action in light of claims that the manufacturer failed to adequately warn doctors and patients about the risk of severe brain disorders, liver damage, and other serious side effects.

Do I have a Zinbryta Lawsuit?

The Pharmaceutical Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Zinbryta lawsuits. We are handling individual litigation nationwide and currently accepting new injury and death cases in all 50 states.

Free Case Evaluation: Again, if you were harmed by Zinbryta, you should contact our law firm immediately. You may be entitled to compensation by filing a suit and our lawyers can help.

Free Confidential Case Evaluation

Verified 100% Secure SiteTo contact us for a free review of your potential case, please fill out the form below or call us toll free 24 hrs/day by dialing: (866) 588-0600.